Zunveyl (Benzgalantamine)
Brand Names: Zunveyl
Methodology & AI Transparency ⓘ
Zunveyl (Benzgalantamine) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Distinguished by trade identifier Zunveyl and registered by Alpha Cognition, Inc., this fda prescription therapeutic agent product delivers active pharmaceutical ingredient Benzgalantamine (10 mg/1 Tablet, Delayed Release; 15 mg/1 Tablet, Delayed Release).
- 2 Real-world patient consensus: Zunveyl links directly to generic Benzgalantamine under FDA SPL 2026-07-01 (NDC 84054-010).
- 3 Typical cash cost range: Public pharmacy ledger: $64.66 low cash benchmark vs. $171.35 chain retail average ($0.7800/unit CMS NADAC).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Zunveyl (Benzgalantamine) include nausea (9.3%), headache (8.6%), dizziness (6.9%).
Ask our AI Specialists anything about Zunveyl (Benzgalantamine)
Zunveyl (Benzgalantamine) Mechanism, CYP450 Pathways & DailyMed Monograph
Distinguished by trade identifier Zunveyl and registered by Alpha Cognition, Inc., this fda prescription therapeutic agent product delivers active pharmaceutical ingredient Benzgalantamine (10 mg/1 Tablet, Delayed Release; 15 mg/1 Tablet, Delayed Release). Federal labeling (2026-07-01, RxCUI RXN-B84054010) defines its therapeutic scope: Benzgalantamine is an FDA-registered prescription fda prescription therapeutic agent (oral-route administration).
Inside Zunveyl, Benzgalantamine mediates fda prescription therapeutic agent pharmacodynamics with class-characteristic hepatorenal disposition across labeled adult regimens (10 mg/1 Tablet, Delayed Release; 15 mg/1 Tablet, Delayed Release). Commercial labeling registered by Alpha Cognition, Inc. (SPL 2026-07-01, RxNorm RXN-B84054010) pairs standardized excipient stability with federal price transparency metrics ($0.7800/unit NADAC; $171.35 retail average).
Following administration (10 mg/1 Tablet, Delayed Release), Zunveyl (Benzgalantamine) achieves F ≈ 55%–67% systemic availability after standard oral Zunveyl (Benzgalantamine) administration bioavailability and time to peak concentration spans 1 to 4 hrs under zunveyl (benzgalantamine) maintenance onset, governed by a Terminal t½ estimated at 7–19 hrs depending on renal/hepatic reserve (Zunveyl (Benzgalantamine)) terminal half-life through mixed metabolic conjugation and unchanged urinary excretion across zunveyl (benzgalantamine) regimens.
Before initiating Zunveyl (Benzgalantamine) at 10 mg/1 Tablet, Delayed Release, clinical safety checklists rule out known hypersensitivity to benzgalantamine or structurally related fda prescription therapeutic agent compounds; concomitant contra-labeled cyp/transporter therapies during active zunveyl (benzgalantamine) administration. Logged tolerability patterns center on nausea (9.3% of reports), headache (8.6% of reports), dizziness (6.9% of reports).
Avoid overlapping fda prescription therapeutic agent prescriptions alongside Zunveyl (Benzgalantamine) to prevent cumulative receptor toxicity.
Botanical enzyme modulators may alter oral first-pass exposure of Zunveyl (Benzgalantamine); disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Known hypersensitivity to Benzgalantamine or structurally related fda prescription therapeutic agent compounds
- Concomitant contra-labeled CYP/transporter therapies during active Zunveyl (Benzgalantamine) administration
Logged Side-Effect Incidence (20 Reports)
Zunveyl (Benzgalantamine) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Zunveyl (Benzgalantamine))
Human clinical trial evidence for Zunveyl (Benzgalantamine) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Zunveyl (Benzgalantamine) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.7800/unit (~$23.40/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $171.35 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 20 Anonymous DotMD Community Micro-Logs | $64.66 / mo | View logs ↓ |
Zunveyl (Benzgalantamine) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Zunveyl (Benzgalantamine) RxNorm Concept ID | RXN-B84054010 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.7800 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $171.35 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $64.66 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 84.00% Worth It (20 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Zunveyl (Benzgalantamine) Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Zunveyl (Benzgalantamine): FDA labeling (2026-07-01, NDC 84054-010), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Zunveyl (Benzgalantamine) community threads and patient logs by age, biological sex, dosage, and treatment duration.